<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose positron...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/2/317 |
| _version_ | 1797410785943617536 |
|---|---|
| author | Freba Ahmaddy Caroline Burgard Leonie Beyer Viktoria Florentine Koehler Peter Bartenstein Matthias P. Fabritius Thomas Geyer Vera Wenter Harun Ilhan Christine Spitzweg Andrei Todica |
| author_facet | Freba Ahmaddy Caroline Burgard Leonie Beyer Viktoria Florentine Koehler Peter Bartenstein Matthias P. Fabritius Thomas Geyer Vera Wenter Harun Ilhan Christine Spitzweg Andrei Todica |
| author_sort | Freba Ahmaddy |
| collection | DOAJ |
| description | Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose positron-emission-tomography/computed-tomography (<sup>18</sup>F-FDG-PET/CT) in the monitoring of functional tumor response compared to morphological response. Methods: In 22 patients, a modified Positron Emission Tomography Response Criteria In Solid Tumors (mPERCIST) evaluation before treatment with Lenvatinib and at 3 and 6 month follow up was performed. Further PET-parameters and morphologic tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were assessed and their prediction of progression-free survival (PFS) and disease-specific survival (DSS) was evaluated. Results: Most patients were rated stable in morphological evaluation and progressive using a metabolic response. All patients who responded to therapy through RECIST showed a decline in nearly all Positron Emission Tomography (PET)-parameters. For both time-points, non-responders according to mPERCIST showed significantly lower median PFS and DSS, whereas according to RECIST, only DSS was significantly lower. Conclusion: Tumor response assessment by <sup>18</sup>F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes. |
| first_indexed | 2024-03-09T04:35:15Z |
| format | Article |
| id | doaj.art-c61cb1b2f3094621a2e9adcff0e1fc7b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T04:35:15Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c61cb1b2f3094621a2e9adcff0e1fc7b2023-12-03T13:29:10ZengMDPI AGCancers2072-66942021-01-0113231710.3390/cancers13020317<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with LenvatinibFreba Ahmaddy0Caroline Burgard1Leonie Beyer2Viktoria Florentine Koehler3Peter Bartenstein4Matthias P. Fabritius5Thomas Geyer6Vera Wenter7Harun Ilhan8Christine Spitzweg9Andrei Todica10Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Radiology, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Radiology, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, GermanyBackground: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose positron-emission-tomography/computed-tomography (<sup>18</sup>F-FDG-PET/CT) in the monitoring of functional tumor response compared to morphological response. Methods: In 22 patients, a modified Positron Emission Tomography Response Criteria In Solid Tumors (mPERCIST) evaluation before treatment with Lenvatinib and at 3 and 6 month follow up was performed. Further PET-parameters and morphologic tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were assessed and their prediction of progression-free survival (PFS) and disease-specific survival (DSS) was evaluated. Results: Most patients were rated stable in morphological evaluation and progressive using a metabolic response. All patients who responded to therapy through RECIST showed a decline in nearly all Positron Emission Tomography (PET)-parameters. For both time-points, non-responders according to mPERCIST showed significantly lower median PFS and DSS, whereas according to RECIST, only DSS was significantly lower. Conclusion: Tumor response assessment by <sup>18</sup>F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes.https://www.mdpi.com/2072-6694/13/2/317differentiated thyroid cancerradioiodine refractoryLenvatinib<sup>18</sup>F-FDG-PET/CT |
| spellingShingle | Freba Ahmaddy Caroline Burgard Leonie Beyer Viktoria Florentine Koehler Peter Bartenstein Matthias P. Fabritius Thomas Geyer Vera Wenter Harun Ilhan Christine Spitzweg Andrei Todica <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib Cancers differentiated thyroid cancer radioiodine refractory Lenvatinib <sup>18</sup>F-FDG-PET/CT |
| title | <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib |
| title_full | <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib |
| title_fullStr | <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib |
| title_full_unstemmed | <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib |
| title_short | <sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib |
| title_sort | sup 18 sup f fdg pet ct in patients with advanced radioiodine refractory thyroid cancer treated with lenvatinib |
| topic | differentiated thyroid cancer radioiodine refractory Lenvatinib <sup>18</sup>F-FDG-PET/CT |
| url | https://www.mdpi.com/2072-6694/13/2/317 |
| work_keys_str_mv | AT frebaahmaddy sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT carolineburgard sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT leoniebeyer sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT viktoriaflorentinekoehler sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT peterbartenstein sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT matthiaspfabritius sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT thomasgeyer sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT verawenter sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT harunilhan sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT christinespitzweg sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib AT andreitodica sup18supffdgpetctinpatientswithadvancedradioiodinerefractorythyroidcancertreatedwithlenvatinib |